"FDA Updates Ozempic Label with Additional Side Effect Warning"

The FDA has accepted Novo Nordisk's proposed changes to the packaging of the popular weight loss drug Ozempic, adding a warning about intestinal blockage. Ozempic, which mimics the body's GLP-1 hormone, has gained popularity for its weight loss effects but has been associated with gastrointestinal side effects. The addition of the warning brings Ozempic in line with other GLP-1 medications that can cause ileus, or intestinal obstructions. Novo Nordisk has emphasized patient safety and stated that the drug's safety and efficacy are supported by the updated labeling.